Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
← catalyst calendarNCT07421739 · readout in 727 d
Sponsored by Aura Biosciences (industry) · AURA — their whole pipeline →. With Vitaccess Ltd.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
15estimated
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-12 | actual | When the study began enrolling |
| Primary completion | 2028-08-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-15 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Choroidal Melanoma
- Indeterminate Lesions
- Uveal Melanoma
- Ocular Melanoma
Intervention
- Other: Non-interventional, digital, patient-reported, real-world study
Primary outcome
what the primary-completion date above is the date OFChange from baseline in EORTC QLQ-C30 scores at month 15 and 24.
measured 24 months
Permalink · AURA's whole pipeline · Catalyst calendar · Every registered study · What changed